nach oben

Applied Health Economics and Health Policy

Erschienen in:

01.02.2013 | Correspondence

A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing

verfasst von: Brian Godman, Lars L. Gustafsson

Erschienen in: Applied Health Economics and Health Policy | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Excerpt

We read the recent paper by Persson and colleagues with interest [1]. However, we think the paper contained some misunderstandings which we believe should be discussed further, as this paper is likely to be widely read both in Sweden and across Europe. …

Persson U, Svensson J, Pettersson B. A new reimbursement system for innovative pharmaceuticals combining value-based and free market pricing. Appl Health Econ Health Policy. 2012;10:217–25.PubMedCrossRef

Wettermark B, Godman B, Andersen K, et al. Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe. Pharmacoeconomics. 2008;26:537–50.PubMedCrossRef

Godman B, Wettermark B, Hoffman M, Anderson K, Haycox A, et al. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Rev Pharmacoecon Outcomes Res. 2009;9:65–83.PubMedCrossRef

Hugosson K, Engstrom A. Threshold value for a QALY: correlation with disease severity and decision uncertainty [abstract]. Value Health. 2008;11(3):A49.CrossRef

Anell A, Persson U. Reimbursement and clinical guidelines for pharmaceuticals in Sweden: do health-economic evaluations support decision making? Eur J Health Econ. 2005;50:274–9.CrossRef

Moïse P, Docteur E. OECD Health Working Papers No. 28. Pharmaceutical pricing and reimbursement in Sweden. 2007. http://www.olis.oecd.org/olis/2007doc.nsf/FREDATCORPLOOK/NT00002E52/$FILE/JT03231887.PDF [Accessed 2008 Feb 2].

The Dental and Pharmaceutical Benefits Agency (TLV). Annual Report 2011. http://www.tlv.se/Upload/Verksamhet/tlv-%C3%A5rsredovisning-2011.pdf [Accessed 2012 Dec 18].

Godman B, Bucsics A, Burkhardt T, Haycox A, Seyfried H, Wieninger P. Insight into recent reforms and initiatives in Austria: implications for key stakeholders. Expert Rev Pharmacoecon Outcomes Res. 2008;8:357–71.PubMedCrossRef

Sermet C, Andrieu V, Godman B, Van Ganse E, Haycox A, Reynier JP. Ongoing pharmaceutical reforms in France: implications for key stakeholder groups. Appl Health Econ Health Policy. 2010;8:7–24.PubMedCrossRef

10.

Godman B, Paterson K, Malmstrom R, et al. Improving the managed entry of new drugs: sharing experiences across Europe. Expert Rev Pharmacoecon Outcomes Res. 2012;12:439–41.PubMedCrossRef

11.

Festoy H, Sveen K, Yu L-M, Gjonnes L, Gregersen T. Norway: pharmaceutical pricing and reimbursement information. 2008. http://ppri.oebig.at/Downloads/Results/Norway_PPRI_2008.pdf [Accessed 2012 Dec 14].

12.

Kolaska K, Schubert S, Manca A, Hermanowski T. A review of health technology assessment (HTA) recommendations for drug therapies issued between 2007 and 2009 and their impact on policymaking processes in Poland. Health Policy. 2011;102:145–51.CrossRef

13.

Voncina L, Strizrep T. Croatia: 2009/2010 pharmaceutical pricing and reimbursement forum. Eurohealth. 2011;16:20–2.

14.

Wettermark B, Persson M, Wilking N, et al. Forecasting drug utilization and expenditure in a metropolitan health region. BMC Health Serv Res. 2010;10:128.PubMedCrossRef

15.

Godman B, Bennie M, Baumgärtel C, Sović Brkičić L, et al. Essential to increase the use of generics in Europe to maintain comprehensive healthcare? Farmeconomia Health Econ Ther Pathways. 2012;13(Suppl. 3):5–20.

16.

Godman B, Shrank W, Wettermark B, Andersen M, Bishop I, et al. Use of generics: a critical cost containment measure for all healthcare professionals in Europe? Pharmaceuticals. 2010;3:2470–94. doi:10.3390/ph/3082470.CrossRef

17.

Garuoliene K, Godman B, Gulbinovič J, Wettermark B, Haycox A. European countries with small populations can obtain low prices for drugs: Lithuania as a case history. Expert Rev Pharmacoecon Outcomes Res. 2011;11:343–9.PubMedCrossRef

18.

van Woerkom M, Piepenbrink JF, Godman B, et al. Ongoing measures to enhance the efficiency of prescribing of PPIs and statins in the Netherlands: influence and future implications. J Comp Eff Res. 2012;1:527–38.

19.

Markovic-Pekovic V, Ranko Škrbić R, Godman B, Gustafsson LL. Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future directions. Expert Rev Pharmacoecon Outcomes Res. 2012;5:661–71.

20.

Bennie M, Godman B, Bishop I, Campbell S. Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland. Expert Rev Pharmacoecon Outcomes Res. 2012;12:125–30.PubMedCrossRef

21.

Taylor L. Australian govt blocks subsidies for new drugs. 2011. http://www.pharmatimes.com/Article/11-03-15/Australian_govt_blocks_subsidies_for_new_drugs.aspx [Accessed 2012 Dec 2].

22.

Garuoliene K, Alonderis T, Marcinkevicius M. Pharmaceutical policy and the effects of the economic crisis: Lithuania. Eurohealth. 2011;17:1–4.

23.

Lexchin J, Kohler J. The danger of imperfect regulation: OxyContin use in the United States and Canada. Int J Risk Saf Med. 2011;23:233–40.PubMed

24.

Godman B, Shrank W, Andersen M, Berg C, Bishop I, Burkhardt, et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilisation: changes seen and global implications. Expert Rev Pharmacoecon Outcomes Res. 2010;10:707–22.

25.

Vončina L, Strizrep T, Godman B, et al. Influence of demand side measures to enhance renin-angiotensin prescribing efficiency in Europe: implications for the future. Expert Rev Pharmacoecon Outcomes Res. 2011;11:469–79.PubMedCrossRef

26.

Norman C, Zarrinkoub R, Hasselström J, Godman B, Granath F, Wettermark B. Potential savings without compromising the quality of care. Int J Clin Pract. 2009;63:1320–6.PubMedCrossRef

27.

Gustafsson LL, Wettermark B, Godman B, Andersén-Karlsson E, Bergman U, et al. The “Wise List”: a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin Pharmacol Toxicol. 2011;108:224–33.PubMedCrossRef

28.

Barrett A, Roques T, Small M, Smith R. How much will Herceptin really cost? BMJ. 2006;33:1118–20.CrossRef

29.

Jack A. Balancing Big Pharma’s books. BMJ. 2008;336:418–9.PubMedCrossRef

30.

Jaroslawski S, Toumi M. Market access agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts. BMC Health Serv Res. 2011;11:259.PubMedCrossRef

31.

Adamski J, Godman B, Ofierska-Sujkowska G, Osinska B, Herholz H, et al. Review of risk sharing schemes for pharmaceuticals: considerations, critical evaluation and recommendations for European payers. BMC Health Serv Res. 2010;10:153. doi:10.1186/1472-6963-10-153.PubMedCrossRef

32.

Cheema PK, Gavura S, Migus M, Godman B, Yeung L, Trudeau M. International variability in the reimbursement of cancer drugs by publically funded drug programs. Curr Oncol. 2012;19:165–76. doi:10.3747/co.19.946.

33.

Jommi C. Managed market entry for drugs in Italy. EMAUD Market Access Newsletter. June 2012. http://www.slideshare.net/Mondher_Toumi/market-access-newsletter-emaud-june2012 [Accessed 2012 Dec 14].

34.

Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med. 2012;366:864–6.PubMedCrossRef

Titel: A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing
verfasst von: Brian Godman
Lars L. Gustafsson
Publikationsdatum: 01.02.2013
Verlag: Springer International Publishing AG
Erschienen in: Applied Health Economics and Health Policy / Ausgabe 1/2013
Print ISSN: 1175-5652
Elektronische ISSN: 1179-1896
DOI: https://doi.org/10.1007/s40258-012-0008-7

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2013

Lessons from Game Theory about Healthcare System Price Inflation

The Economic Evaluation of Medical Devices

Assessing the Cost Utility of Response-Guided Therapy in Patients with Chronic Hepatitis C Genotype 1 in the UK Using the MONARCH Model

A Systematic Review of Economic Evaluations in Second and Later Lines of Therapy for the Treatment of Non-Small Cell Lung Cancer

Pipeline™ Embolization Device for the Treatment of Complex Intracranial Aneurysms

Authors’ Reply to Godman and Gustafsson: “A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing”